S&P 500   4,271.19 (-0.07%)
DOW   33,908.83 (-0.21%)
QQQ   327.82 (-0.20%)
AAPL   173.49 (-0.61%)
MSFT   289.95 (-0.47%)
META   173.00 (-1.06%)
GOOGL   119.22 (-0.28%)
AMZN   141.28 (-0.58%)
TSLA   909.31 (-0.29%)
NVDA   184.50 (+0.63%)
NIO   19.85 (-1.15%)
BABA   89.35 (-0.47%)
AMD   98.25 (-0.02%)
MU   61.97 (+0.57%)
T   18.38 (-0.22%)
CGC   3.80 (-6.40%)
F   15.89 (-0.87%)
GE   79.37 (-0.69%)
DIS   122.09 (-0.59%)
AMC   21.02 (-1.59%)
PYPL   97.81 (-1.62%)
PFE   48.97 (-0.61%)
NFLX   240.88 (-0.11%)
S&P 500   4,271.19 (-0.07%)
DOW   33,908.83 (-0.21%)
QQQ   327.82 (-0.20%)
AAPL   173.49 (-0.61%)
MSFT   289.95 (-0.47%)
META   173.00 (-1.06%)
GOOGL   119.22 (-0.28%)
AMZN   141.28 (-0.58%)
TSLA   909.31 (-0.29%)
NVDA   184.50 (+0.63%)
NIO   19.85 (-1.15%)
BABA   89.35 (-0.47%)
AMD   98.25 (-0.02%)
MU   61.97 (+0.57%)
T   18.38 (-0.22%)
CGC   3.80 (-6.40%)
F   15.89 (-0.87%)
GE   79.37 (-0.69%)
DIS   122.09 (-0.59%)
AMC   21.02 (-1.59%)
PYPL   97.81 (-1.62%)
PFE   48.97 (-0.61%)
NFLX   240.88 (-0.11%)
S&P 500   4,271.19 (-0.07%)
DOW   33,908.83 (-0.21%)
QQQ   327.82 (-0.20%)
AAPL   173.49 (-0.61%)
MSFT   289.95 (-0.47%)
META   173.00 (-1.06%)
GOOGL   119.22 (-0.28%)
AMZN   141.28 (-0.58%)
TSLA   909.31 (-0.29%)
NVDA   184.50 (+0.63%)
NIO   19.85 (-1.15%)
BABA   89.35 (-0.47%)
AMD   98.25 (-0.02%)
MU   61.97 (+0.57%)
T   18.38 (-0.22%)
CGC   3.80 (-6.40%)
F   15.89 (-0.87%)
GE   79.37 (-0.69%)
DIS   122.09 (-0.59%)
AMC   21.02 (-1.59%)
PYPL   97.81 (-1.62%)
PFE   48.97 (-0.61%)
NFLX   240.88 (-0.11%)
S&P 500   4,271.19 (-0.07%)
DOW   33,908.83 (-0.21%)
QQQ   327.82 (-0.20%)
AAPL   173.49 (-0.61%)
MSFT   289.95 (-0.47%)
META   173.00 (-1.06%)
GOOGL   119.22 (-0.28%)
AMZN   141.28 (-0.58%)
TSLA   909.31 (-0.29%)
NVDA   184.50 (+0.63%)
NIO   19.85 (-1.15%)
BABA   89.35 (-0.47%)
AMD   98.25 (-0.02%)
MU   61.97 (+0.57%)
T   18.38 (-0.22%)
CGC   3.80 (-6.40%)
F   15.89 (-0.87%)
GE   79.37 (-0.69%)
DIS   122.09 (-0.59%)
AMC   21.02 (-1.59%)
PYPL   97.81 (-1.62%)
PFE   48.97 (-0.61%)
NFLX   240.88 (-0.11%)
NASDAQ:LUCD

Lucid Diagnostics - LUCD Stock Forecast, Price & News

$3.00
-0.04 (-1.32%)
(As of 08/18/2022 10:02 AM ET)
Add
Compare
Today's Range
$3.00
$3.05
50-Day Range
$1.73
$3.45
52-Week Range
$1.69
$13.52
Volume
1,800 shs
Average Volume
116,658 shs
Market Capitalization
$113.79 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$10.54

Lucid Diagnostics MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
251.4% Upside
$10.54 Price Target
Short Interest
Healthy
4.53% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.55mentions of Lucid Diagnostics in the last 14 days
Based on 8 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Decreasing
From ($1.42) to ($1.51) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.78 out of 5 stars

Medical Sector

891st out of 1,122 stocks

Surgical & Medical Instruments Industry

85th out of 112 stocks

LUCD stock logo

About Lucid Diagnostics (NASDAQ:LUCD) Stock

Lucid Diagnostics Inc. operates as a commercial-stage medical diagnostics technology company. The company focuses on patients with gastroesophageal reflux disease, which is also known as chronic heartburn, acid reflux, or simply reflux, who are at risk of developing esophageal precancer and cancer, specifically highly lethal esophageal adenocarcinoma. Its lead products include EsoGuard, a laboratory developed esophageal DNA test; and EsoCheck, an esophageal cell collection device. The company was incorporated in 2018 and is based in New York, New York. Lucid Diagnostics Inc. is a subsidiary of PAVmed Inc.

Wall Street Analysts Forecast Growth

A number of research analysts recently issued reports on the company. Ascendiant Capital Markets cut their price objective on Lucid Diagnostics to $13.00 in a research note on Thursday, June 9th. Needham & Company LLC cut their price objective on Lucid Diagnostics from $5.00 to $4.25 and set a "buy" rating for the company in a research note on Tuesday. Canaccord Genuity Group cut their price objective on Lucid Diagnostics from $12.00 to $8.00 in a research note on Thursday, May 12th. Finally, BTIG Research reiterated a "buy" rating and set a $5.00 price objective on shares of Lucid Diagnostics in a research note on Friday, May 13th. Seven investment analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the company presently has an average rating of "Buy" and an average price target of $11.61.

Lucid Diagnostics Trading Down 7.3 %

NASDAQ:LUCD opened at $3.04 on Thursday. The stock's 50 day moving average is $2.57 and its 200 day moving average is $2.76. Lucid Diagnostics has a 12 month low of $1.69 and a 12 month high of $13.52. The stock has a market cap of $115.32 million and a PE ratio of -1.93.

Receive LUCD Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Lucid Diagnostics and its competitors with MarketBeat's FREE daily newsletter.

LUCD Stock News Headlines

Lucid Diagnostics launches test centers in 3 states
See More Headlines
Receive LUCD Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Lucid Diagnostics and its competitors with MarketBeat's FREE daily newsletter.

LUCD Company Calendar

Last Earnings
3/28/2022
Today
8/18/2022
Next Earnings (Estimated)
11/22/2022
Fiscal Year End
12/31/2022

Industry, Sector and Symbol

Industry
Surgical & medical instruments
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:LUCD
Fax
N/A
Employees
2,021
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$10.54
High Stock Price Forecast
$21.00
Low Stock Price Forecast
$4.25
Forecasted Upside/Downside
+251.4%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
6 Analysts

Profitability

Net Income
$-28,080,000.00
Pretax Margin
-6,553.85%

Debt

Sales & Book Value

Annual Sales
$500,000.00
Book Value
$0.96 per share

Miscellaneous

Free Float
N/A
Market Cap
$113.79 million
Optionable
Not Optionable
Beta
N/A

Key Executives

  • Dr. Lishan Aklog M.D. (Age 56)
    Chairman & CEO
  • Mr. Dennis M. McGrath CPA (Age 65)
    CFO, Pres & Sec.
  • Dr. Sanford D. Markowitz M.D.
    Ph.D., Cofounder & Strategic Advisor, Member of the Medical Advisor Board
  • Dr. Joseph Willis M.D.
    Cofounder, Strategic Advisor & Member of Medical Advisory Board
  • Dr. Amitabh Chak M.D.
    Cofounder, Strategic Advisor & Member of Medical Advisory Board
  • Mr. Shaun M. O'Neill M.B.A. (Age 40)
    Exec. VP & COO
  • Richard D. Yazbeck
    Chief Technology Officer
  • Dr. Suman M. Verma M.D.
    Ph.D., Chief Scientific Officer
  • Mr. Adrian K. Miller
    VP of Investor Relations
  • Dr. Brian J. deGuzman M.D. (Age 57)
    Chief Compliance Officer













LUCD Stock - Frequently Asked Questions

Should I buy or sell Lucid Diagnostics stock right now?

6 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Lucid Diagnostics in the last year. There are currently 6 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" LUCD shares.
View LUCD analyst ratings
or view top-rated stocks.

What is Lucid Diagnostics' stock price forecast for 2022?

6 brokers have issued 12 month price targets for Lucid Diagnostics' stock. Their LUCD share price forecasts range from $4.25 to $21.00. On average, they predict the company's stock price to reach $10.54 in the next year. This suggests a possible upside of 246.8% from the stock's current price.
View analysts price targets for LUCD
or view top-rated stocks among Wall Street analysts.

How have LUCD shares performed in 2022?

Lucid Diagnostics' stock was trading at $5.37 at the beginning of the year. Since then, LUCD shares have decreased by 43.4% and is now trading at $3.04.
View the best growth stocks for 2022 here
.

When is Lucid Diagnostics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, November 22nd 2022.
View our LUCD earnings forecast
.

How were Lucid Diagnostics' earnings last quarter?

Lucid Diagnostics Inc. (NASDAQ:LUCD) issued its quarterly earnings data on Monday, March, 28th. The company reported ($0.32) EPS for the quarter, missing analysts' consensus estimates of ($0.20) by $0.12.

When did Lucid Diagnostics IPO?

(LUCD) raised $75 million in an initial public offering (IPO) on Thursday, October 14th 2021. The company issued 5,000,000 shares at $14.00-$16.00 per share.

What is Lucid Diagnostics' stock symbol?

Lucid Diagnostics trades on the NASDAQ under the ticker symbol "LUCD."

Who are Lucid Diagnostics' major shareholders?

Lucid Diagnostics' stock is owned by a number of retail and institutional investors. Top institutional investors include Luminus Management LLC (2.30%), Nantahala Capital Management LLC (0.81%), Geneos Wealth Management Inc. (0.11%), Millennium Management LLC (0.06%), Bank of Montreal Can (0.04%) and LPL Financial LLC (0.04%).

How do I buy shares of Lucid Diagnostics?

Shares of LUCD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Lucid Diagnostics' stock price today?

One share of LUCD stock can currently be purchased for approximately $3.04.

How much money does Lucid Diagnostics make?

Lucid Diagnostics (NASDAQ:LUCD) has a market capitalization of $115.31 million and generates $500,000.00 in revenue each year. The company earns $-28,080,000.00 in net income (profit) each year or ($1.57) on an earnings per share basis.

How many employees does Lucid Diagnostics have?

The company employs 2,021 workers across the globe.

How can I contact Lucid Diagnostics?

The official website for the company is www.luciddx.com. The company can be reached via phone at 212-949-4319 or via email at pavmed@lavoiehealthscience.com.

This page (NASDAQ:LUCD) was last updated on 8/18/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.